GERD: Gastroesophageal reflux disease; NSAIDs: Non-steroidal anti-inflammatory drugs; OR: Odds ratio; PRR: Pooled risk ratio; No drug-drug interaction; sustained relief; Supported by Meal independent dosing
Meta-analysis of 92 controlled trials of NSAIDs reported pooled dyspepsia percents and PRR by three dyspepsia definitions: strict, loose, and loose-less-heartburn.1
Strict: Terms synonymous with epigastric pain/discomfort; Loose: ‘Strict’ definition plus terms for heartburn, nausea, bloating, anorexia and vomiting; Loose-less-heartburn: ‘Loose’ definition without heartburn terms.
NSAIDs usage is associated with:
Increase in dyspepsia risk (p<0.05) by 36%.*1
*Using the ‘strict’ definition, based solely on epigastric pain-related symptoms
Increase in development of GERD by ~4 times, OR=4.23.2
Heartburn development in 68% of patients and significant increase in acute reflux symptoms, p<0.0001, alone or in combination with aspirin.2
Vono-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers